JP Morgan Chase’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.51M Buy
+51,500
New +$1.37M ﹤0.01% 4487
2024
Q1
– Sell
-54,000
Closed -$795K – 7374
2023
Q4
$795K Buy
+54,000
New +$828K ﹤0.01% 4498

Other funds holding AMLX

JP Morgan Chase's AMLX Position: Q3 2026 in Review

JP Morgan Chase increased its Amylyx Pharmaceuticals (AMLX) stake by 84% in Q3 2026, buying an estimated $41.6M and bringing the position to 3,434,449 shares worth $101M. The position accounts for 0.01% of the portfolio, ranked #1042.

JP Morgan Chase first reported a position in AMLX in Q1 2022 and has held it in 19 quarters since. 227 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • JP Morgan Chase held 3,434,449 shares of Amylyx Pharmaceuticals worth $101M as of Q3 2026.
  • JP Morgan Chase bought 1,570,799 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $41.6M.
  • Amylyx Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q3 2026, its #1042 holding.
  • JP Morgan Chase first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 19 quarters since.
  • 227 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.